{"id":67226,"date":"2026-06-03T19:34:18","date_gmt":"2026-06-03T11:34:18","guid":{"rendered":"https:\/\/flcube.com\/?p=67226"},"modified":"2026-06-03T19:34:19","modified_gmt":"2026-06-03T11:34:19","slug":"everest-medicines-secures-1-14-billion-deal-with-travere-therapeutics-for-next-gen-btk-inhibitor-civorebrutinib-in-global-kidney-disease-market","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=67226","title":{"rendered":"Everest Medicines Secures $1.14 Billion Deal with Travere Therapeutics for Next-Gen BTK Inhibitor Civorebrutinib in Global Kidney Disease Market"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>Everest Medicines<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/1952:HKG\">HKG: 1952<\/a>) announced a <strong>strategic licensing agreement<\/strong> with <strong>Travere Therapeutics, Inc.<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/TVTX:NASDAQ\">NASDAQ: TVTX<\/a>), granting the U.S. company <strong>exclusive development and commercialization rights<\/strong> to <strong>civorebrutinib (EVER001)<\/strong> outside Greater China and select Southeast Asian markets in a deal worth up to <strong>$1.14 billion<\/strong>.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">The transaction includes an <strong>$112.5 million upfront payment<\/strong> and potential <strong>$1.03 billion in development, regulatory, and commercial milestones<\/strong> across up to five indications, plus <strong>tiered royalties from high single-digit to double-digit percentages<\/strong> on annual net sales, validating civorebrutinib&#8217;s <strong>best-in-class potential<\/strong> as a next-generation covalent reversible Bruton&#8217;s tyrosine kinase (BTK) inhibitor for immune-mediated kidney diseases.<\/p>\n\n\n\n<h2 id=\"h-transaction-structure-amp-financial-terms\" class=\"wp-block-heading\">Transaction Structure &amp; Financial Terms<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Component<\/th><th>Amount\/Details<\/th><\/tr><\/thead><tbody><tr><td><strong>Upfront Payment<\/strong><\/td><td>$112.5 million<\/td><\/tr><tr><td><strong>Development Milestones<\/strong><\/td><td>Up to $1.03 billion across five indications<\/td><\/tr><tr><td><strong>Royalty Structure<\/strong><\/td><td>High single-digit to double-digit tiered percentages on net sales<\/td><\/tr><tr><td><strong>Total Deal Value<\/strong><\/td><td>Up to $1.14 billion<\/td><\/tr><tr><td><strong>Territory<\/strong><\/td><td>Worldwide excluding Greater China and certain Southeast Asian countries<\/td><\/tr><tr><td><strong>Rights Granted<\/strong><\/td><td>Exclusive development and commercialization<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-drug-profile-amp-therapeutic-indications\" class=\"wp-block-heading\">Drug Profile &amp; Therapeutic Indications<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Molecule<\/strong>: Civorebrutinib (EVER001)<\/li>\n\n\n\n<li><strong>Class<\/strong>: Next-generation covalent reversible Bruton&#8217;s tyrosine kinase (BTK) inhibitor<\/li>\n\n\n\n<li><strong>Differentiation<\/strong>: Best-in-class potential with improved selectivity and safety profile<\/li>\n\n\n\n<li><strong>Primary Indications<\/strong>:<\/li>\n\n\n\n<li>Primary membranous nephropathy (PMN)<\/li>\n\n\n\n<li>IgA nephropathy<\/li>\n\n\n\n<li>Minimal change disease (MCD)<\/li>\n\n\n\n<li>Focal segmental glomerulosclerosis (FSGS)<\/li>\n\n\n\n<li>Lupus nephritis<\/li>\n\n\n\n<li><strong>Therapeutic Area<\/strong>: Immune-mediated kidney diseases with significant unmet medical need<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-asset-origin-amp-development-history\" class=\"wp-block-heading\">Asset Origin &amp; Development History<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Entity<\/th><th>Role<\/th><\/tr><\/thead><tbody><tr><td><strong>Evopoint Biosciences Co., Ltd.<\/strong><\/td><td>Original developer (Chinese biotech)<\/td><\/tr><tr><td><strong>SinoMab BioScience Ltd.<\/strong> (HKEX: 3681)<\/td><td>Co-development partner<\/td><\/tr><tr><td><strong>Everest Medicines<\/strong> (HKG: 1952)<\/td><td>Global development and commercialization lead for kidney disease indications<\/td><\/tr><tr><td><strong>Travere Therapeutics<\/strong> (NASDAQ: TVTX)<\/td><td>Ex-China commercial partner with nephrology expertise<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-strategic-rationale-amp-synergies\" class=\"wp-block-heading\">Strategic Rationale &amp; Synergies<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Travere&#8217;s Expertise<\/strong>: Established commercial infrastructure and clinical development experience in rare kidney diseases<\/li>\n\n\n\n<li><strong>Everest&#8217;s Innovation<\/strong>: Access to capital while retaining Greater China rights and significant milestone upside<\/li>\n\n\n\n<li><strong>Market Opportunity<\/strong>: Addresses large patient populations across multiple orphan and non-orphan kidney disease indications<\/li>\n\n\n\n<li><strong>Risk Mitigation<\/strong>: Partnership de-risks development costs while maintaining substantial financial participation<\/li>\n\n\n\n<li><strong>Global Acceleration<\/strong>: Travere&#8217;s resources expected to accelerate clinical development across multiple indications simultaneously<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-competitive-landscape-analysis\" class=\"wp-block-heading\">Competitive Landscape Analysis<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>BTK Inhibitor Market<\/strong>: Growing class with applications expanding beyond oncology into autoimmune and inflammatory conditions<\/li>\n\n\n\n<li><strong>Kidney Disease Focus<\/strong>: Limited treatment options for many immune-mediated glomerular diseases create high-value opportunities<\/li>\n\n\n\n<li><strong>Differentiation<\/strong>: Covalent reversible mechanism may offer improved safety profile over irreversible BTK inhibitors<\/li>\n\n\n\n<li><strong>First-Mover Potential<\/strong>: Opportunity to establish standard of care in multiple underserved nephrology indications<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-strategic-implications-for-everest-medicines\" class=\"wp-block-heading\">Strategic Implications for Everest Medicines<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Capital Generation<\/strong>: $112.5 million upfront provides non-dilutive funding for pipeline advancement<\/li>\n\n\n\n<li><strong>Global Validation<\/strong>: Partnership with established U.S. nephrology company validates asset quality<\/li>\n\n\n\n<li><strong>Risk-Reward Balance<\/strong>: Retains valuable Greater China rights while monetizing international potential<\/li>\n\n\n\n<li><strong>Pipeline Focus<\/strong>: Enables resource allocation to other pipeline assets including oncology and infectious disease programs<\/li>\n\n\n\n<li><strong>Partnership Model<\/strong>: Demonstrates successful execution of asset-centric business development strategy<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-market-impact-considerations\" class=\"wp-block-heading\">Market Impact Considerations<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Treatment Paradigm<\/strong>: Potential to transform standard of care across multiple immune-mediated kidney diseases<\/li>\n\n\n\n<li><strong>Commercial Strategy<\/strong>: Travere&#8217;s orphan drug expertise supports premium pricing and rapid market penetration<\/li>\n\n\n\n<li><strong>Patient Access<\/strong>: Accelerated development timeline could bring effective treatments to patients years earlier<\/li>\n\n\n\n<li><strong>Healthcare Economics<\/strong>: Effective disease-modifying therapy may reduce long-term dialysis and transplant costs<\/li>\n\n\n\n<li><strong>Competitive Response<\/strong>: Deal likely to trigger increased interest in BTK inhibitors for non-oncology indications<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Forward-Looking Statements<\/strong><br>This brief contains forward-looking statements regarding partnership terms, clinical development, regulatory pathways, and commercial potential for civorebrutinib. Actual results may differ due to clinical trial outcomes, regulatory decisions, and competitive dynamics.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Everest Medicines (HKG: 1952) announced a strategic licensing agreement with Travere Therapeutics, Inc. (NASDAQ: TVTX),&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[126,1164,33,4770],"class_list":["post-67226","post","type-post","status-publish","format-standard","hentry","category-company","category-deals","tag-everest-medicines","tag-hkg-1952","tag-tkis-egfr-vegf-btk-etc","tag-travere-therapeutics"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v27.7) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Everest Medicines Secures $1.14 Billion Deal with Travere Therapeutics for Next-Gen BTK Inhibitor Civorebrutinib in Global Kidney Disease Market - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Everest Medicines (HKG: 1952) announced a strategic licensing agreement with Travere Therapeutics, Inc. (NASDAQ: TVTX), granting the U.S. company exclusive development and commercialization rights to civorebrutinib (EVER001) outside Greater China and select Southeast Asian markets in a deal worth up to $1.14 billion.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=67226\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Everest Medicines Secures $1.14 Billion Deal with Travere Therapeutics for Next-Gen BTK Inhibitor Civorebrutinib in Global Kidney Disease Market\" \/>\n<meta property=\"og:description\" content=\"Everest Medicines (HKG: 1952) announced a strategic licensing agreement with Travere Therapeutics, Inc. (NASDAQ: TVTX), granting the U.S. company exclusive development and commercialization rights to civorebrutinib (EVER001) outside Greater China and select Southeast Asian markets in a deal worth up to $1.14 billion.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=67226\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-06-03T11:34:18+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-06-03T11:34:19+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=67226#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=67226\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Everest Medicines Secures $1.14 Billion Deal with Travere Therapeutics for Next-Gen BTK Inhibitor Civorebrutinib in Global Kidney Disease Market\",\"datePublished\":\"2026-06-03T11:34:18+00:00\",\"dateModified\":\"2026-06-03T11:34:19+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=67226\"},\"wordCount\":563,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Everest Medicines\",\"HKG: 1952\",\"TKIs (EGFR VEGF BTK etc.)\",\"Travere Therapeutics\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=67226#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=67226\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=67226\",\"name\":\"Everest Medicines Secures $1.14 Billion Deal with Travere Therapeutics for Next-Gen BTK Inhibitor Civorebrutinib in Global Kidney Disease Market - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-06-03T11:34:18+00:00\",\"dateModified\":\"2026-06-03T11:34:19+00:00\",\"description\":\"Everest Medicines (HKG: 1952) announced a strategic licensing agreement with Travere Therapeutics, Inc. (NASDAQ: TVTX), granting the U.S. company exclusive development and commercialization rights to civorebrutinib (EVER001) outside Greater China and select Southeast Asian markets in a deal worth up to $1.14 billion.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=67226#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=67226\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=67226#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Everest Medicines Secures $1.14 Billion Deal with Travere Therapeutics for Next-Gen BTK Inhibitor Civorebrutinib in Global Kidney Disease Market\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Everest Medicines Secures $1.14 Billion Deal with Travere Therapeutics for Next-Gen BTK Inhibitor Civorebrutinib in Global Kidney Disease Market - Insight, China&#039;s Pharmaceutical Industry","description":"Everest Medicines (HKG: 1952) announced a strategic licensing agreement with Travere Therapeutics, Inc. (NASDAQ: TVTX), granting the U.S. company exclusive development and commercialization rights to civorebrutinib (EVER001) outside Greater China and select Southeast Asian markets in a deal worth up to $1.14 billion.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=67226","og_locale":"en_US","og_type":"article","og_title":"Everest Medicines Secures $1.14 Billion Deal with Travere Therapeutics for Next-Gen BTK Inhibitor Civorebrutinib in Global Kidney Disease Market","og_description":"Everest Medicines (HKG: 1952) announced a strategic licensing agreement with Travere Therapeutics, Inc. (NASDAQ: TVTX), granting the U.S. company exclusive development and commercialization rights to civorebrutinib (EVER001) outside Greater China and select Southeast Asian markets in a deal worth up to $1.14 billion.","og_url":"https:\/\/flcube.com\/?p=67226","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-06-03T11:34:18+00:00","article_modified_time":"2026-06-03T11:34:19+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=67226#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=67226"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Everest Medicines Secures $1.14 Billion Deal with Travere Therapeutics for Next-Gen BTK Inhibitor Civorebrutinib in Global Kidney Disease Market","datePublished":"2026-06-03T11:34:18+00:00","dateModified":"2026-06-03T11:34:19+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=67226"},"wordCount":563,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Everest Medicines","HKG: 1952","TKIs (EGFR VEGF BTK etc.)","Travere Therapeutics"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=67226#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=67226","url":"https:\/\/flcube.com\/?p=67226","name":"Everest Medicines Secures $1.14 Billion Deal with Travere Therapeutics for Next-Gen BTK Inhibitor Civorebrutinib in Global Kidney Disease Market - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-06-03T11:34:18+00:00","dateModified":"2026-06-03T11:34:19+00:00","description":"Everest Medicines (HKG: 1952) announced a strategic licensing agreement with Travere Therapeutics, Inc. (NASDAQ: TVTX), granting the U.S. company exclusive development and commercialization rights to civorebrutinib (EVER001) outside Greater China and select Southeast Asian markets in a deal worth up to $1.14 billion.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=67226#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=67226"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=67226#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Everest Medicines Secures $1.14 Billion Deal with Travere Therapeutics for Next-Gen BTK Inhibitor Civorebrutinib in Global Kidney Disease Market"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/67226","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=67226"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/67226\/revisions"}],"predecessor-version":[{"id":67227,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/67226\/revisions\/67227"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=67226"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=67226"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=67226"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}